Background Acute respiratory infections, mostly in the form of pneumonia, are the leading causes of death in children under five years of age in low income countries. Some clinical trials have demonstrated that vitamin A supplementation reduces the severity of respiratory infections and mortality in children with measles. Objective To determine whether adjunctive vitamin A is effective in children diagnosed with non-measles pneumonia. 
Background
Acute respiratory tract infections (ARIs) and vitamin A deficiency are important public health problems in many low income countries. Vitamin A deficiency is associated with impaired humoral and cellular immune function, keratinisation of the respiratory epithelium and decreased mucus secretion, which weaken barriers to infection (Ross 1996) . In low income countries, ARIs, mostly in the form of pneumonia, are the leading cause of death in children under five years of age. The incidence of clinical pneumonia in low income countries is estimated at 0.29 episodes per child per year. This equates to an annual incidence of 150.7 million new cases, 11 to 20 million (7% to 13%) of which are severe enough to require hospital admission. No comparable data are available for high income countries. However, from large population-based studies, the incidence of community-acquired pneumonia among children less than five years of age is approximately 0.026 episodes per child per year (Rundan 2004) . Pneumonia is associated with and causes about 3.8 million childhood deaths annually; 30.3% of these are in children under the age of five (Kirkwood 1995) . Community-based clinical trials have been conducted in order to determine whether periodic high-dose vitamin A supplementation reduces the incidence, severity or both of acute respiratory infections in children. The association between vitamin A deficiency and child mortality was first observed in the 1930s when vitamin A supplementation significantly reduced mortality among measles patients (Ellison 1932) . Two meta-analyses (Fawzi 1993; Glasziou 1993) examined the relationship between vitamin A supplementation and infectious diseases. Glasziou (Glasziou 1993) reported that vitamin A reduced all-cause mortality by one third in children in low income countries. However, the reduction in deaths from respiratory disease was seen only in the measles studies. Fawzi (Fawzi 1993 ) also reported that supplementation was protective against overall mortality in community-based studies (odds ratio (OR) 0.70) and highly protective against mortality in hospitalised patients with measles (OR 0.39). From the current evidence it appears that vitamin A supplementation reduces the severity of respiratory infection and other systemic complications of measles. However, the association between vitamin A and non-measles ARIs is unclear. The World Health Organization (WHO) Programme for the Control of Acute Respiratory Infections published a meta-analysis to assess the impact of supplementation on pneumonia morbidity and mortality (VAPWG 1995) . They reported no consistent overall protective or detrimental effect on pneumonia-specific mortality and no effect on the incidence or the prevalence of pneumonia. Hospital-based clinical trials examining the effectiveness of high-dose vitamin A, administered during an acute episode of non-measles do-0620.pdf http://www.medicinacomplementar.com.br/convertido/do-0620.htm ARI, in reducing morbidity or mortality, have been performed. However, no meta-analyses have been carried out. Given the apparent effectiveness of vitamin A in reducing mortality in hospitalised patients with measles, and the inexpensiveness of the intervention, clarification of the association between vitamin A and non-measles ARIs is of some importance.
Results

Discussion
Vitamin A supplementation appears to have had little effect on the clinical course of non-measles pneumonia in children. The lack of a clear beneficial effect after vitamin A treatment is a little surprising given the protective effects of vitamin A in pneumonia associated with measles. Headaches, loss of appetite, vomiting and bulging fontanelles in infants are some of the adverse effects known to occasionally occur with the administration of high doses of vitamin A. These symptoms are minor and transitory, with no known long-term effects, and require no special treatment (Huiming 2005) . From three included studies in this review (Fawzi 1998; Nacul 1999; Stephensen 1998) , the incidence of toxicity as an adverse event was not statistically different between the vitamin A and placebo-treated groups.
There was a borderline relative increase in the placebo group of children who failed to respond satisfactorily to first line antibiotic treatment. However, only one study reported on this and whether it represents a consistent effect of vitamin A, or is the result of chance, needs further investigation. Rodriguez (Rodriguez 2005) conducted a subgroup analysis according to the serum retinol concentration, and found vitamin A can shorten the duration of signs in children with normal serum retinol (> 200 ug/L) but no benefit in children with vitamin A deficiency. However, this trial did not report on the nutritional status and severity of illness, which may be confounding factors. This study also found the time to remission of respiratory signs did not differ significantly between the groups of normal weight children and those of underweight children. However, data regarding this issue was unavailable to review. Supplemental vitamin A in a lower dose seems to result in a beneficial effect on recurrent bronchopneumonia. This finding was from one study of poor methodological quality and lacking nutritional information about the vitamin A status of included children (Zhang 1999). More well-designed, large randomised controlled trials are needed to support this positive finding.
Fawzi (Fawzi 1998 ) observed a trend towards a higher incidence of death in the vitamin A group (13 of 346 participants versus 8 of 341 in the placebo group) although this was not statistically significant (OR 1.63; 95% CI 0.66 to 3.97).
Stephensen (Stephensen 1998) reported more severe clinical scores in children receiving vitamin A than those who received a placebo. We expect that studies in the future will provide more conclusive evidence. The possible explanation for the lack of benefit of vitamin A in non-measles pneumonia is that the effects of vitamin A may be diseasespecific, with vitamin A only being effective when pneumonia is complicated with measles. The benefit of vitamin A as an adjunct to the treatment of non-measles pneumonia was not clarified, but vitamin A might be beneficial to children with high basal serum retinol. Further randomised controlled trials, possibly with measured vitamin A levels and varying vitamin A doses, may provide sufficient evidence to clarify the role of vitamin A in non-measles pneumonia.
Reviewers' conclusions Implications for practice
From the evidence available at this time and given the lack of clinical benefit associated with vitamin A treatment in children with non-measles pneumonia, it is difficult to recommend vitamin A as an adjunctive therapy in this patient group, particularly if the risk of vitamin A deficiency is low.
Implications for research
Even though six studies met the inclusion criteria, the variability in the outcomes reported and measured meant that only results from a few studies were eligible for inclusion in the meta-analyses for each of the outcomes. This limited the power of the meta-analyses to detect statistically significant differences. Large randomised controlled trials reporting clinically important outcomes are needed to increase the likelihood of obtaining a true and precise estimate of the effect. However, dosage of vitamin A could also be important and randomised controlled trials with a risk-stratified population, that is children at high risk and low risk of vitamin A deficiency, and varying administered dosage may provide evidence of the effectiveness of vitamin A treatment for non-measles pneumonia in children.
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